Marine Fidelle

Inserm — France

Medicine · Health Sciences

15h-index7.9kcitations73works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(34), Gut microbiota and health(26), Immune Cell Function and Interaction(8), Clostridium difficile and Clostridium perfringens research(8), Diet and metabolism studies(8)

Publications73 total

Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Nature Medicine·2026· 1 citedOpen Access
Soluble MAdCAM-1 in metastatic renal cell carcinoma
Figshare·2026Open Access
Soluble MAdCAM-1 in metastatic renal cell carcinoma
Figshare·2026Open Access
Tryptophan metabolite indole-3-acetate: a new culprit in irinotecan-induced gut epithelial injury
Gut·2025
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease
Molecular Cancer·2025· 1 citedOpen Access
EP.04.29 Tobacco-Related Atheromatous Disease as Eligibility Criteria for Lung Cancer Screening: A Prospective Evaluation
Journal of Thoracic Oncology·2025
8The actionable microbial gut checkpoint MAdCAM-1 in patients with advanced renal cell carcinoma
The Oncologist·2025Open Access
P1.04.39 Markov Model Approach to Optimize Lung Cancer Screening and Early Detection in Patients With Smoking Associated Diseases
Journal of Thoracic Oncology·2025
Supplementary Figures S1 to S9 from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
Table S4 from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
Table S3 from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
Table S1 from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
Data from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
Table S2 from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
Table S5 from Gut Microbiota Modulation through <i>Akkermansia</i> spp<i>.</i> Supplementation Increases CAR T-cell Potency
2025Open Access
LBA62 Phase I trial of camu camu prebiotic plus immunotherapy in patients with melanoma and non-small cell lung cancer (NSCLC)
Annals of Oncology·2025Open Access
2599MO Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma: Results from three independent clinical trials
Annals of Oncology·2025
19MO Desaminotyrosine is a key driver of the success of immunotherapy with fecal microbial transplantation in cancer
ESMO Open·2025Open Access
2808MO Impact of proton pump inhibitors use and potency on Immunotherapy (ICI) outcomes and gut microbiome in advanced NSCLC and RCC
Annals of Oncology·2025
144P Subclinical cholestasis as a hallmark of gut dysbiosis causing resistance to cancer immunotherapy
Annals of Oncology·2025
page 1 of 4Next →

Frequent Co-authors

Laurence Zitvogel(42), Guido Kroemer(30), Lisa Derosa(29), Nicola Segata(18), Bertrand Routy(16), Carolina Alves Costa Silva(15), Gladys Ferrere(14), Sylvère Durand(14), Edoardo Pasolli(13), Pierre Ly(13), Valerio Iebba(12), Cassandra Thélémaque(12), Romain Daillère(11), Safae Terrisse(11), Laurence Albigès(10), Anne‐Gaëlle Goubet(10), Roxanne Birebent(10), Peng Liu(9), Oliver Kepp(9), Bertrand Routy(8)